Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) and Inhibrx (NASDAQ:INBX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.
Analyst Recommendations
This is a breakdown of current ratings for Evaxion Biotech A/S and Inhibrx, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evaxion Biotech A/S | 0 | 0 | 2 | 0 | 3.00 |
| Inhibrx | 0 | 0 | 4 | 0 | 3.00 |
Evaxion Biotech A/S presently has a consensus target price of $9.00, indicating a potential upside of 1,009.60%. Inhibrx has a consensus target price of $44.33, indicating a potential upside of 96.60%. Given Evaxion Biotech A/S’s higher probable upside, equities research analysts plainly believe Evaxion Biotech A/S is more favorable than Inhibrx.
Volatility and Risk
Profitability
This table compares Evaxion Biotech A/S and Inhibrx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evaxion Biotech A/S | N/A | -452.78% | -126.54% |
| Inhibrx | -28,749.25% | -5,168.31% | -74.66% |
Institutional & Insider Ownership
0.6% of Evaxion Biotech A/S shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx shares are owned by institutional investors. 41.6% of Evaxion Biotech A/S shares are owned by company insiders. Comparatively, 25.8% of Inhibrx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Evaxion Biotech A/S and Inhibrx’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evaxion Biotech A/S | N/A | N/A | -$23.17 million | ($0.98) | -0.83 |
| Inhibrx | $2.19 million | 449.66 | -$145.23 million | ($4.05) | -5.57 |
Evaxion Biotech A/S has higher earnings, but lower revenue than Inhibrx. Inhibrx is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.
Summary
Evaxion Biotech A/S beats Inhibrx on 6 of the 11 factors compared between the two stocks.
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
About Inhibrx
Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.
Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.
